RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID
Aim. To evaluate risk of repeated atherothrombotic events in patients survived acute coronary syndrome (ACS) and having poorly reduced platelet aggregation (proven by optical aggregometry) in response to acetylsalicylic acid (ASA) therapy.Material and methods. 200 patients with ACS (aged 56,6±9,2 y....
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2016-01-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/734 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839641398057369600 |
|---|---|
| author | N. F. Puchinyan N. V. Furman A. R. Kiselev Ya. P. Dovgalevsky |
| author_facet | N. F. Puchinyan N. V. Furman A. R. Kiselev Ya. P. Dovgalevsky |
| author_sort | N. F. Puchinyan |
| collection | DOAJ |
| description | Aim. To evaluate risk of repeated atherothrombotic events in patients survived acute coronary syndrome (ACS) and having poorly reduced platelet aggregation (proven by optical aggregometry) in response to acetylsalicylic acid (ASA) therapy.Material and methods. 200 patients with ACS (aged 56,6±9,2 y.o.) were included in the study. Platelet functional activity during ASA therapy was evaluated with laser aggregometer. ASA resistance was defined if the summarizing index of platelet aggregation (induced with ADP, 5 mμml/l) was 50% or higher during ASA therapy. Observation period was 18±6 months. Atherothrombotic events (unstable angina, myocardial infarction, stroke, cardiovascular death) were considered.Results. Lack ASA response rate was about 12%. Totally 22 repeated atherothrombotic events were registered: 5,6% among ASA sensitive patients and 50% - among ASA resistant patients. Repeated atherothrombotic events were registered in ASA resistance patients during first 14 days. ASA sensitive patients showed repeated atherothrombotic events in some months after ACS. The relative risk of cardiovascular event in ASA resistance patients was 8,92 (CI 95% 4,39; 17,84 р=0,05).Conclusion. The high level of the induced platelet aggregation (proven by laser aggregometry) points to high risk of repeated atherothrombotic events in patients with ACS. |
| format | Article |
| id | doaj-art-310ab3a2a72c46ffb5540e0c819bc79f |
| institution | Matheson Library |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-310ab3a2a72c46ffb5540e0c819bc79f2025-07-03T07:28:27ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532016-01-0156414610.20996/1819-6446-2009-5-6-41-46733RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACIDN. F. Puchinyan0N. V. Furman1A. R. Kiselev2Ya. P. Dovgalevsky3Saratov Research Institute for CardiologySaratov Research Institute for CardiologySaratov Research Institute for CardiologySaratov Research Institute for CardiologyAim. To evaluate risk of repeated atherothrombotic events in patients survived acute coronary syndrome (ACS) and having poorly reduced platelet aggregation (proven by optical aggregometry) in response to acetylsalicylic acid (ASA) therapy.Material and methods. 200 patients with ACS (aged 56,6±9,2 y.o.) were included in the study. Platelet functional activity during ASA therapy was evaluated with laser aggregometer. ASA resistance was defined if the summarizing index of platelet aggregation (induced with ADP, 5 mμml/l) was 50% or higher during ASA therapy. Observation period was 18±6 months. Atherothrombotic events (unstable angina, myocardial infarction, stroke, cardiovascular death) were considered.Results. Lack ASA response rate was about 12%. Totally 22 repeated atherothrombotic events were registered: 5,6% among ASA sensitive patients and 50% - among ASA resistant patients. Repeated atherothrombotic events were registered in ASA resistance patients during first 14 days. ASA sensitive patients showed repeated atherothrombotic events in some months after ACS. The relative risk of cardiovascular event in ASA resistance patients was 8,92 (CI 95% 4,39; 17,84 р=0,05).Conclusion. The high level of the induced platelet aggregation (proven by laser aggregometry) points to high risk of repeated atherothrombotic events in patients with ACS.https://www.rpcardio.online/jour/article/view/734acute coronary syndromeantiaggregantstherapy efficacycardiovascular сomplications |
| spellingShingle | N. F. Puchinyan N. V. Furman A. R. Kiselev Ya. P. Dovgalevsky RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID Рациональная фармакотерапия в кардиологии acute coronary syndrome antiaggregants therapy efficacy cardiovascular сomplications |
| title | RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID |
| title_full | RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID |
| title_fullStr | RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID |
| title_full_unstemmed | RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID |
| title_short | RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID |
| title_sort | risk of repeated thrombotic events in patients survived acute coronary syndrome and having laboratory proven resistance to acetylsalicylic acid |
| topic | acute coronary syndrome antiaggregants therapy efficacy cardiovascular сomplications |
| url | https://www.rpcardio.online/jour/article/view/734 |
| work_keys_str_mv | AT nfpuchinyan riskofrepeatedthromboticeventsinpatientssurvivedacutecoronarysyndromeandhavinglaboratoryprovenresistancetoacetylsalicylicacid AT nvfurman riskofrepeatedthromboticeventsinpatientssurvivedacutecoronarysyndromeandhavinglaboratoryprovenresistancetoacetylsalicylicacid AT arkiselev riskofrepeatedthromboticeventsinpatientssurvivedacutecoronarysyndromeandhavinglaboratoryprovenresistancetoacetylsalicylicacid AT yapdovgalevsky riskofrepeatedthromboticeventsinpatientssurvivedacutecoronarysyndromeandhavinglaboratoryprovenresistancetoacetylsalicylicacid |